The treatment is being described as a potential game-changer.
A trial of a new injection which prevents someone catching HIV has been cut short because it was so successful.
Experts at GlaxoSmithKline didn't feel it was necessary to continue, after finding the jab 69% more effective than taking a daily pill known as prep.
It's given every two months, and has been described as a potential game-changer.
“It’s really exciting,” Jared Baeten, an epidemiologist at the University of Washington told Science Mag.
“It gives another option for people who can’t or don’t want to take daily pills.”
